Information Provided By: 
Fly News Breaks for September 4, 2018
RIGL
Sep 4, 2018 | 07:08 EDT
JPMorgan analyst Anupam Rama raised his price target for Rigel Pharmaceuticals to $7 and reiterates an Overweight rating on the shares. The Tavalisse launch in chronic immune thrombocytopenia, progress on the follow-on indication of autoimmune hemolytic anemia, and potential outside the U.S. partnership progress should drive upside near- and long-term, Rama tells investors in a research note.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
